|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Zentalis Pharmaceuticals, Llc (ZNTL) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
84,924,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
22,000 |
22,000 |
22,000 |
| Total Buy Value |
$0 |
$219,391 |
$219,391 |
$219,391 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
28,862 |
28,862 |
163,808 |
358,673 |
| Total Sell Value |
$332,692 |
$332,692 |
$4,021,263 |
$8,732,198 |
| Total People Sold |
4 |
4 |
7 |
7 |
| Total Sell Transactions |
6 |
6 |
12 |
34 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vultaggio Vincent |
Principal Accounting OfficerOf |
• – – |
2024-04-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,458 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2024-02-12 |
4 |
AS |
$11.44 |
$13,419 |
D/D |
(1,173) |
643,277 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2024-02-12 |
4 |
AS |
$11.44 |
$29,435 |
D/D |
(2,573) |
451,449 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2024-02-02 |
4 |
AS |
$11.54 |
$133,310 |
D/D |
(11,552) |
644,450 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2024-02-02 |
4 |
AS |
$11.54 |
$100,040 |
D/D |
(8,669) |
454,022 |
|
- |
|
| Lackner Mark |
Chief Scientific Officer |
• – – |
2024-02-02 |
4 |
S |
$11.54 |
$18,291 |
D/D |
(1,585) |
195,728 |
|
- |
|
| Paul Andrea |
Chief Legal Officer |
• – – |
2024-02-02 |
4 |
S |
$11.54 |
$38,197 |
D/D |
(3,310) |
149,973 |
|
- |
|
| Blackwell Kimberly |
Chief Executive Officer |
• • – |
2024-02-01 |
4 |
D |
$11.69 |
$241,457 |
D/D |
(20,655) |
484,145 |
|
- |
|
| Blackwell Kimberly |
Chief Executive Officer |
• • – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
504,800 |
|
- |
|
| Gallagher Cam |
President |
• • – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
192,500 |
656,002 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
462,691 |
|
- |
|
| Lackner Mark |
Chief Scientific Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
141,000 |
197,313 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
337,500 |
377,232 |
|
- |
|
| Paul Andrea |
Chief Legal Officer |
• – – |
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
153,283 |
|
- |
|
| Lackner Mark |
Chief Scientific Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
56,313 |
|
- |
|
| Lackner Mark |
Chief Scientific OfficerOffice |
• – – |
2023-12-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,313 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2023-12-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
24,158 |
834,931 |
|
- |
|
| Blackwell Kimberly |
Chief Executive Officer |
• • – |
2023-11-13 |
4 |
B |
$10.29 |
$51,448 |
D/D |
5,000 |
254,800 |
2.81 |
- |
|
| Johnson David Michael |
Director |
– • – |
2023-11-10 |
4 |
B |
$9.88 |
$167,943 |
D/D |
17,000 |
144,389 |
2.39 |
- |
|
| Brownstein Carrie |
Chief Medical Officer |
• – – |
2023-10-04 |
4 |
AS |
$19.43 |
$207,298 |
D/D |
(10,628) |
105,685 |
|
- |
|
| Bunker Kevin D. |
Chief Scientific Officer |
• – – |
2023-10-04 |
4 |
AS |
$19.43 |
$118,355 |
D/D |
(6,068) |
859,089 |
|
- |
|
| Epperly Melissa B, |
Chief Financial Officer |
• – – |
2023-10-04 |
4 |
AS |
$19.43 |
$106,926 |
D/D |
(5,482) |
387,691 |
|
- |
|
| Skvarka Jan |
Director |
– • – |
2023-09-11 |
4 |
AS |
$25.05 |
$125,238 |
D/D |
(5,000) |
47,970 |
|
- |
|
| Johnson David Michael |
Director |
– • – |
2023-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,059 |
127,389 |
|
- |
|
| Kariuki Enoch |
Director |
– • – |
2023-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
16,364 |
38,181 |
|
- |
|
237 Records found
|
|
Page 1 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
